In vitro alternatives for toxicology screening and animal testing are increasing in variety. While validation against animal tests is costly and may result in false rejection, human clinical and/or mechanistic data is revolutionizing our acceptance and understanding of these tests. Such knowledge will serve to guide our future testing strategies.

We will explore some of the complexities and successes met in the validation and acceptance of in vitro toxicology tests, highlighting how strides in adverse outcome pathways stand to benefit toxicology and drug development. In addition, we will discuss the advantages of in silico technologies in TK/PK studies.


  • Warren Casey, PhD, Director, U.S. National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), National Institutes of Environmental Health Sciences (NIEHS)
  • Doug Learn, PhD, Director, Photobiology and Cellular Therapeutic Safety
  • Leon Stankowski, PhD, Scientific Director, Genetic and In Vitro Toxicology
  • Jeroen Rijk, PhD, Study Director, Discovery
  • Clive Roper, PhD, BSc, CBiol, CSci, MRSB, Head, In Vitro Sciences